KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Capital Expenditures (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Capital Expenditures for 8 consecutive years, with -$159000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 112.76% to -$159000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $509000.0 through Dec 2025, down 60.08% year-over-year, with the annual reading at $509000.0 for FY2025, 60.08% down from the prior year.
  • Capital Expenditures hit -$159000.0 in Q4 2025 for Adaptive Biotechnologies, up from -$1.2 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $30.2 million in Q2 2021 to a low of -$1.2 million in Q3 2025.
  • Historically, Capital Expenditures has averaged $3.8 million across 5 years, with a median of $1.4 million in 2023.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 1388.02% in 2023 and later plummeted 335.66% in 2025.
  • Year by year, Capital Expenditures stood at $9.2 million in 2021, then tumbled by 109.73% to -$900000.0 in 2022, then soared by 244.22% to $1.3 million in 2023, then dropped by 4.01% to $1.2 million in 2024, then crashed by 112.76% to -$159000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ADPT at -$159000.0 in Q4 2025, -$1.2 million in Q3 2025, and $1.7 million in Q2 2025.